Trial Profile
Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 05 Apr 2018 Status changed from recruiting to discontinued.
- 29 Jan 2013 New trial record